Recruiting PHASE2 INTERVENTIONAL 1-arm NCT07103395

A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer

A Phase II Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade (PD-1/CTLA-4) in Patients With Locally Advanced Non-Small Cell Lung Cancer

Sponsor: Sun Yat-sen University

Conditions Lung Cancer (NSCLC)

Interventions Consolidative therapy Neoadjuvant therapy Radiotherapy

Updated 2 times since 2025 Last updated: Jan 12, 2026 Started: Jan 1, 2026 Primary completion: Dec 30, 2029 Completion: Dec 30, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Lung Cancer (NSCLC), this trial is actively recruiting participants. The trial is conducted by Sun Yat-sen University and has accumulated 2 data snapshots since 2026. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

2 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Sep 2025 — Feb 2026 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sun Yat-sen University

Data source: Sun Yat-sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China